Other studies suggest that lenalidomide, a drug that is associated with a lower level of toxicity than thalidomide and which is primarily employed in the treatment of multiple myeloma, might theoretically confer benefits in the management of anti-myelin-associated glycoprotein neuropathy [45,46]. This evidence concerns the gene MAG and neuropathy.